Understanding highly adaptable cancer cells in lung adenocarcinoma
Official title: Determining the role and function of a high plasticity cell state in lung adenocarcinoma
Funded at Sloan-Kettering Inst Can Research · NIH-11138420 · Data updated 2026-11-12
This work explores how certain highly adaptable cancer cells contribute to lung adenocarcinoma growth and resistance to treatments.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 22, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $249,526 |
| NIH project number | 5K08CA267072-04 |
| Project ID | NIH-11138420 on NIH RePORTER |
Who could benefit from this research
✓Could help
This foundational work focuses on understanding cancer biology and does not currently involve direct patient participation, but future clinical applications would target patients with lung adenocarcinoma.
✕Less likely to help
Patients whose cancer does not involve this specific type of highly adaptable cell state may not directly benefit from therapies developed from this particular line of research.
What this research studies
We are learning about special cancer cells in lung adenocarcinoma that can change their characteristics, which helps tumors grow and resist therapy. Our team first found these adaptable cells in mouse lung tumors and then confirmed their presence in human lung adenocarcinoma samples. We believe these cells are key drivers of cancer progression and treatment failure. By understanding how these cells work, we hope to find new ways to fight lung cancer.
Why it matters
Potential benefit: If successful, this work could lead to new treatment strategies that target these adaptable cancer cells, potentially improving outcomes for patients with lung adenocarcinoma.
How similar studies have gone: While the concept of tumor plasticity is recognized, this research aims to specifically define and target a newly identified high plasticity cell state in lung adenocarcinoma, representing a novel approach.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Chan, Jason Earl — Sloan-Kettering Inst Can Research
- Study coordinator: Chan, Jason Earl
Related research
Other NIH-funded projects on the same topics.
-
Understanding a highly flexible cell state in lung cancer that worsens outcomes
A doctor-scientist at Cedars-Sinai wants to learn how a highly adaptable lung cancer cell state drives disease progression and resistance to therapy, using models that resemble human tumors.
-
Breaking cytokine loops in LKB1-mutant lung cancer and the immune system
A researcher at NYU School of Medicine is studying why a common lung cancer subtype with a specific mutation doesn’t respond well to current immunotherapy, with the aim of finding new ways to improve treatment.
-
Lung Adenocarcinoma: From Genome Changes to New Therapies
This NIH grant supports research on lung adenocarcinoma to better understand its genome changes and translate that knowledge into better diagnosis and treatments for patients.
-
Understanding how lung cancer and immune cells influence each other in early lung cancer development
A study looks at how lung cells and immune cells change together as early lung cancer (lung adenocarcinoma) develops, with the goal of finding points to intervene early.
-
Targeting a cancer pathway to stop metastasis in SMARCA4-deficient lung cancer
This grant aims to understand and interrupt a key pathway that drives spread of a specific type of lung cancer in people whose tumors have SMARCA4 mutations.
-
Combining imaging and biopsy genes to spot aggressive vs. slow-growing early lung cancer before surgery
Aimed at people with early-stage lung adenocarcinoma, this project tests a combined imaging and biopsy gene‑marker approach to better predict tumor aggressiveness before surgery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.